During the PQA Annual Meeting in Baltimore, MD, Laura Cranston, RpH, CEO of Pharmacy Quality Alliance (PQA), discusses the organization's recently-developed measures on behalf of CMS.

Laura Cranston, RpH: So, PQA as a measure developer initially focused on developing medication related measures on behalf of CMS for use of the Medicare Part D program. As our mission continues to evolve, PQA is now developing measures, for example, that look at drug therapy resolution following a medication therapy management session. And this is not strictly limited to Medicare. The measure that we just endorsed today can also be used in commercial populations as well.